# A Study to Assess the Efficacy and Safety of Oral CL-H1T in the Treatment of Acute Migraine Pain

> **NCT03877718** · PHASE2 · COMPLETED · sponsor: **Charleston Laboratories, Inc** · enrollment: 475 (actual)

## Conditions studied

- Migraine
- Pain
- Nausea
- Vomiting
- Aura

## Interventions

- **DRUG:** Arm 1: CL-H1T
- **DRUG:** Arm 2: CL-H1T
- **DRUG:** Arm 3: Sumatriptan Succinate 100 mg capsule
- **DRUG:** Arm 4: Promethazine HCl 18.75 mg
- **DRUG:** Arm 5: Promethazine HCl 37.5 mg
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03877718
- **Lead sponsor:** Charleston Laboratories, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-01
- **Primary completion:** 2019-08-27
- **Final completion:** 2019-08-27
- **Target enrollment:** 475 (ACTUAL)
- **Last updated:** 2019-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03877718

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03877718, "A Study to Assess the Efficacy and Safety of Oral CL-H1T in the Treatment of Acute Migraine Pain". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT03877718. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*